ɫ�����ֱ��

New Iridium, a company developing commercialized photocatalysis technologies to accelerate drug development and manufacturing, has been awarded a National Science Foundation (NSF) Small Business Technology Transfer (STTR) grant for $256,000 to conduct research and development work on facilitating timely availability of Remdesivir, a potential life-saving drug in the global fight against COVID-19.

This award will enable further research into the unique electromechanical failure mechanism in HASEL actuators, a new class of smart, soft, high-speed robotic hardware.

Researchers at ɫ�����ֱ��, led by Professor Mike McGehee in the College of Engineering and Applied Science, have developed an improved method for controlling smart tinting on windows that could make them cheaper, more effective and more durable than current options on the market.

ɫ�����ֱ�� biomedical engineer Jacob Segil is working to bring back a sense of touch for amputees, including veterans of the wars in Iraq and Afghanistan.

ɫ�����ֱ�� researchers and the CU spinoff VitriVax Inc., are focused on finding a way to get vaccines to 7.8 billion people. The research team is able to do so with funding, licensing and startup support from Venture Partners at ɫ�����ֱ��, the university’s commercialization arm.

Researchers are fast-tracking a new CU-born technology, SickStick, in hopes of not only helping to curb the current pandemic but also radically change the way we track disease in the future.

The next businesses to make a splash will come out of Colorado’s research institutions, including ɫ�����ֱ��. Venture Partners' Managing Director Bryn Rees is featured in the article.

Vu, an assistant professor in the Department of Computer Science, is improving human cognitive functions using an ear-worn device. To bring the technology to customers worldwide later in 2020, he founded Earable Inc., which now has more than 15 employees.

Randolph, a professor in the Department of Chemical and Biological Engineering, founded VitriVax, a ɫ�����ֱ�� spinout, to commercialize new applications of atomic layer deposition techniques for producing thermally stable vaccines.

Funding will support the ongoing development of a nascent RNA drug screen.